First FDA-Approved Biosimilar for Multiple Sclerosis Mimics Tysabri
- On August 24, 2023, the United States Food and Drug Administration approved Tyruko, natalizumab-sztn, a biosimilar for Tysabri (natalizumab), an injectable biologic for managing multiple sclerosis. The drug has also been indicated to manage moderate-to-severe Crohn’s disease (CD) for patients with inflammation who have not responded to other...
